Jefferies Group’s Anika Therapeutics ANIK Stock Holding History

Jefferies Group’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-50,615	Closed	-$1.91M	–	1333
2020 Q2	$1.91M	Sell	50,615 -815	-2%	-$26.9K	0.02%	573
2020 Q1	$1.47M	Buy	51,430 +37,657	+273%	+$1.52M	0.02%	824
2019 Q4	$714K	Buy	13,773 +2,330	+20%	+$135K	0.01%	1640
2019 Q3	$628K	Buy	11,443 +6,008	+111%	+$308K	﹤0.01%	1759
2019 Q2	$221K	Sell	5,435 -85,510	-94%	-$3.12M	﹤0.01%	2078
2019 Q1	$2.75M	Buy	+90,945	New	+$3.11M	0.02%	732
2018 Q3	–	Sell	-6,856	Closed	-$271K	–	2368
2018 Q2	$219K	Buy	+6,856	New	+$282K	﹤0.01%	1987
2017 Q3	–	Sell	-4,108	Closed	-$203K	–	2304
2017 Q2	$203K	Sell	4,108 -1,693	-29%	-$78K	﹤0.01%	2035
2017 Q1	$252K	Buy	+5,801	New	+$277K	﹤0.01%	1915
2014 Q3	–	Sell	-5,484	Closed	-$254K	–	2123
2014 Q2	$254K	Buy	+5,484	New	+$244K	﹤0.01%	1622

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

Jefferies Group's ANIK Position: Q3 2020 in Review

Jefferies Group sold out of Anika Therapeutics (ANIK) in Q3 2020, closing a stake of 50,615 shares — an estimated $1.91M sold.

Jefferies Group first reported a position in ANIK in Q2 2014 and held it in 10 quarters. The position peaked at $2.75M in Q1 2019. 156 funds tracked by Wall St. Rank hold ANIK as of Q3 2020.

Jefferies Group reported no remaining Anika Therapeutics position as of Q3 2020 after selling out during the quarter.
Jefferies Group sold 50,615 Anika Therapeutics shares in Q3 2020, an estimated $1.91M.
Jefferies Group first reported a position in Anika Therapeutics in Q2 2014 and held it in 10 quarters.
Jefferies Group's Anika Therapeutics position peaked at $2.75M in Q1 2019.
156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.